Ethylene Oxide Attorney in North Haven, Connecticut

The Trump Exemption as Evidence of Political Influence

In July 2025, the Trump administration issued an executive proclamation that exempted certain EtO sterilization facilities — including the Covidien/Medtronic North Haven operation — from the EPA's 2024 emission reduction rules. These rules, finalized under the Biden administration, would have required commercial sterilizers to reduce EtO emissions by up to 90%. The exemption was granted after intensive lobbying by the medical device industry, which argued that compliance would disrupt the supply of sterilized medical devices.

For plaintiffs' attorneys, the Trump exemption is a double-edged sword. On one hand, the exemption means that the North Haven facility will continue operating under weaker emission standards, potentially increasing community exposure. On the other hand, the exemption itself — and the lobbying campaign that produced it — can be presented to juries as evidence that the sterilization industry used political influence to avoid safety requirements that the EPA had determined were necessary to protect public health. This narrative of corporate influence undermining environmental protection is powerful in front of juries.

Medtronic's Corporate Resources and Defense Strategy

Medtronic is one of the world's largest medical device companies, with annual revenues exceeding $30 billion. Its acquisition of Covidien in 2015 for $49.9 billion brought the North Haven sterilization facility into Medtronic's portfolio. Medtronic has the financial resources to mount an aggressive and prolonged defense of EtO claims, and the company's medical device business gives it relationships with expert witnesses in toxicology, epidemiology, and regulatory science that can be leveraged in litigation.

Connecticut's three-year statute of limitations for personal injury and the state's regulatory enforcement history through the Department of Energy and Environmental Protection (DEEP) create the framework for North Haven litigation. Claimants should be aware that Medtronic's defense will likely emphasize the facility's compliance with Connecticut state regulations and argue that the EPA's 2016 risk assessment overstates EtO's carcinogenicity — arguments that have had mixed success in other jurisdictions but that Medtronic's resources allow it to present with significant expert support.